Boston Scientific and Scivita Medical announced that they entered into an expanded strategic cooperation arrangement focused on endoscopic technology. Scivita, a China-based medtech company, provides minimally invasive diagnosis and treatment solutions. It focuses on R&D and commercialization for medical endoscopes and related products. The company aims to globalize its operations through strategic cooperations with companies […]
Boston Scientific
Axonics stockholders approve Boston Scientific acquisition
Axonics (Nasdaq:AXNX) announced that its stockholders voted to adopt its $3.7 billion merger agreement with Boston Scientific . Boston Scientific announced its intent to buy Axonics on Jan. 8. Irvine, California-based Axonics develops neuromodulation systems for treating urinary and bowel dysfunction. Its fourth-generation R20 rechargeable sacral neuromodulation (SNM) system received FDA approval around a year ago. […]
Boston Scientific has positive Agent DCB study results
Boston Scientific reported positive investigational device exemption (IDE) trial data for its Agent drug-coated balloon (DCB). The DCB just this month won FDA approval for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. Agent serves as an alternative to […]
FTC reportedly may scrutinize Boston Scientific’s Axonics deal
Bloomberg reports that the U.S. Federal Trade Commission (FTC) may look into the $3.7 billion acquisition of Axonics (Nasdaq:AXNX) by Boston Scientific . A new Axonics regulatory filing with the SEC discloses that the companies refiled their Hart Scott Rodino (HSR) Act notification to the FTC on March 4 — a move that companies sometimes […]
FDA approves Boston Scientific’s Agent drug-coated balloon
Boston Scientific announced today that it received FDA approval for its Agent drug-coated balloon (DCB). The DCB won approval for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. Marlborough, Massachusetts–based Boston Scientific plans a U.S. launch for Agent in […]
Boston Scientific prices €2B offering to finance Axonics buy
Boston Scientific announced that it priced an offering worth nearly $2.2 billion (€2 billion) in senior notes. American Medical Systems Europe B.V., Boston Scientific’s wholly-owned finance subsidiary, priced the public offering. It includes €750,000,000 aggregate principal amount of 3.375% notes due in 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due in 2032. Notes […]
How GLP-1s tanked and reshaped the medtech stock market in 2023
Analysts weigh in on how the GLP-1 craze caused one of the biggest swings in the medtech stock market in recent years.
In a tumultuous year for the medtech industry, the combination of strong sales growth and promising clinical trial results from glucagon-like peptide 1 agonists (GLP-1s) created a seismic shift in the medtech stock market, triggering one of the largest dips in market value that analysts have seen in years. While analysts said the medtech stock market […]
Boston Scientific completes first commercial Farapulse cases in U.S.
Boston Scientific has completed the first post-FDA approval cases in the U.S. with its Farapulse pulsed field ablation system. In a LinkedIn post, Nick Spadea-Anello, president, Electrophysiology, Boston Scientific, announced the first commercial use for the AFib treatment. Marlborough, Massachusetts-based Boston Scientific won the approval for Farapulse last month. In doing so, it became second […]
Layoffs in medtech: These companies recently reduced their workforce
The workforce reduction trend has swept the economy recently, and unfortunately, the medtech space is not immune to layoffs. You’ve probably read about the ongoing layoffs sweeping the tech industry, media and more. For instance, Yahoo, Disney, Zoom and more all reported workforce reductions as companies across industries grapple with economic pressures. Think inflation, supply […]
FDA expands approval for Boston Scientific spinal cord stim to include chronic back pain without prior back surgery
Boston Scientific announced today that the FDA approved an expanded indication for its WaveWriter spinal cord stimulation (SCS) systems. The indication covers chronic low back and leg pain in people without prior back surgery — called non-surgical back pain (NSBP). Boston Scientific says first-line treatment for people with chronic back pain tends to have limitations. […]
What’s next for Boston Scientific after Farapulse’s FDA approval?
Chief Medical Officer Dr. Ken Stein explains the plans at Boston Scientific after its landmark pulsed field ablation approval. On Jan. 31, Boston Scientific became the second company to receive FDA approval for a pulsed field ablation (PFA) system that treats AFib. The landmark approval came just over a month after Medtronic became the first […]